SiBone (NASDAQ:SIBN) Stock Gets Price Target Boost from TD Cowen

SiBone (NASDAQ:SIBN) had its price objective upped by stock analysts at TD Cowen from $20.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price target would suggest a potential upside of 1.30% from the stock’s previous close.

Several other research analysts also recently commented on SIBN. Needham & Company LLC lowered their price objective on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of SiBone in a report on Tuesday. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Truist Financial lifted their price target on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, UBS Group boosted their price target on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.83.

SiBone Price Performance

SIBN traded up $2.48 on Tuesday, hitting $22.70. 491,862 shares of the stock were exchanged, compared to its average volume of 615,715. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -66.57 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. SiBone has a 12 month low of $11.48 and a 12 month high of $22.95. The business has a 50-day moving average of $19.42 and a two-hundred day moving average of $16.45.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. Sell-side analysts forecast that SiBone will post -0.40 EPS for the current fiscal year.

Insider Activity at SiBone

In other SiBone news, SVP Michael Pisetsky sold 29,665 shares of the firm’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $22.11, for a total value of $655,893.15. Following the sale, the senior vice president owned 164,444 shares in the company, valued at $3,635,856.84. This trade represents a 15.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey W. Dunn sold 20,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $18.47, for a total transaction of $369,400.00. Following the sale, the director directly owned 16,057 shares in the company, valued at approximately $296,572.79. The trade was a 55.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 238,371 shares of company stock worth $4,738,916 in the last 90 days. 4.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On SiBone

Several large investors have recently bought and sold shares of the company. First Light Asset Management LLC boosted its stake in shares of SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after purchasing an additional 2,774,795 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after purchasing an additional 182,465 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock valued at $5,969,000 after buying an additional 238,219 shares during the period. Squarepoint Ops LLC increased its stake in shares of SiBone by 40.3% in the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock valued at $1,928,000 after buying an additional 33,947 shares during the period. Finally, Granahan Investment Management LLC raised its holdings in SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after buying an additional 858,942 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors.

Trending Headlines about SiBone

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Third-quarter results exceeded estimates. SiBone reported a loss of $0.08 per share, narrower than the $0.13 analyst consensus, while revenue increased 14.5% year over year to $55.7 million, slightly above expectations. The improved earnings performance may support the stock. Si-Bone Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: Growth and cash generation improved. U.S. procedure volume grew approximately 20%, the active U.S. physician base rose 16% to 1,770, adjusted EBITDA increased 32.4% to $3.0 million, and operating cash flow reached $5.9 million. SiBone ended the quarter with $146.3 million in cash. SiBone Third-Quarter Results
• Positive Sentiment: Product and reimbursement catalysts remain in place. FDA clearance for the iFuse Granite Onyx breakthrough device and new reimbursement rules that could increase hospital payments by up to approximately $50,000 for qualifying procedures may accelerate adoption.
• Neutral Sentiment: Full-year revenue guidance is essentially unchanged. SiBone forecast fiscal 2026 revenue of $231 million to $233 million, compared with the $232.2 million consensus estimate. The guidance is reassuring but does not represent a material forecast increase. The company remains unprofitable, posting a $3.6 million quarterly net loss.
• Negative Sentiment: Insiders sold shares. SVP Michael Pisetsky sold 29,665 shares for about $655,893, reducing his position by 15.28%, while Anshul Maheshwari sold 3,738 shares for $84,105. Both retained sizable holdings, but the transactions could create modest sentiment pressure. SiBone Insider Sales

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.